Rheumatoid Arthritis: Can Drug Tapering Maintain

What did the rheumatoid arthritis tapering trial find?

Researchers compared stepwise reduction of biologic or targeted synthetic disease-modifying antirheumatic drugs, known as DMARDs, with unchanged treatment. In the per-protocol analysis, low disease activity persisted in 88.2% of the tapering group and 89.6% of the continuation group. Most participants whose disease worsened regained control after treatment was increased under the protocol. [Randomized trial](https://pubmed.ncbi.nlm.nih.gov/42839723/).

Noninferiority means the results stayed within a prespecified acceptable difference; it does not establish identical effectiveness. The margin was 10 percentage points. Some secondary disease activity measures favored continuation, and the short follow-up leaves long-term joint protection uncertain. [Trial methods and results](https://pubmed.ncbi.nlm.nih.gov/42839723/).

Why do some rheumatoid arthritis tapering studies reach different conclusions?

The separate SORAIRO trial illustrates that uncertainty. It studied spacing doses of the TNF inhibitor ozoralizumab or reducing accompanying methotrexate, compared with continued treatment. Across the overall study population, neither reduction strategy demonstrated noninferiority for maintaining low disease activity at 48 weeks. Participants already in remission had more encouraging results in a subgroup analysis, but that finding does not establish that every patient in remission can taper successfully. [SORAIRO trial](https://pubmed.ncbi.nlm.nih.gov/41763966/).

This distinction matters because low disease activity can include residual inflammation, while remission represents tighter control. The EULAR recommendations labeled the 2025 update and published in 2026 allow consideration of DMARD tapering during sustained remission, while emphasizing that stopping treatment often triggers a flare. Together, the evidence supports selecting patients carefully rather than applying one dose-reduction policy to everyone taking an advanced arthritis medicine. [EULAR recommendations](https://doi.org/10.1016/j.ard.2026.01.023).

How should patients and rheumatologists approach medication reduction?

The American College of Rheumatology's 2021 guideline conditionally favors continuing an effective DMARD regimen over reducing it. When reduction is considered, it recommends at least six months at the treatment target and assumes that a therapeutic dose of at least one DMARD will remain. Reducing treatment can mean lowering a dose or extending the interval between doses; it does not automatically mean stopping medication. [ACR treatment guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC9273041/).

A practical discussion should establish which medicine would change, how disease activity would be reassessed and whom to contact if symptoms worsen. The same guideline calls for close evaluation during tapering and prompt restoration of the previous regimen if a flare occurs. Patients should agree on those steps with their rheumatology team before changing injections or tablets themselves. [ACR tapering recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC9273041/).